盘前异动 | 百济神州逆市涨超2%，替雷利珠单抗在美国正式上市-To The Moon - Tiger Brokers Online Investing Community

Like
1
Favorite

盘前异动 | 百济神州逆市涨超2%，替雷利珠单抗在美国正式上市

老虎资讯综合10-09

本周三（10月9日），在中概股普遍大跌的背景下，百济神州美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。

消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。

据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。

中金此前指出，ODAC更新PD-1治疗ESCC+G/GEJ投票进展，该建议仅可能影响百泽安的未来获批Label，但不会影响百泽安的美国上市申报进度。

该行认为，随着公司全球收入持续增长，经营效率逐步提高，GAAP经营利润有望在未来1-2 个季度内实现扭亏。关注核心管线和早期实体瘤管线进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

freshman1
·10-09
cool！
Reply
2
Report
Fold Replies
- freshman1:
  isdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaefiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaeisdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouasozhsngiejsle
  10-09
  Reply
  Report
- freshman1:
  fiest repost
  10-09
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1186599914?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2024-10-09 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186599914","market":"us","top_or_hot":-1,"title":"盘前异动 | 百济神州逆市涨超2%， 替雷利珠单抗在美国正式上市","media":"老虎资讯综合","content":"<html><head></head><body><p>本周三（10月9日），在中概股普遍大跌的背景下， <a href=\"https://laohu8.com/S/BGNE\">百济神州</a> 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cd011c248875bdd5b6ca99df21d4878d\" title=\"\" tg-width=\"1224\" tg-height=\"1306\"/></p><p>消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。</p><p>据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。</p><p>中金此前指出，ODAC更新PD-1治疗ESCC+G/GEJ投票进展，该建议仅可能影响百泽安的未来获批Label，但不会影响百泽安的美国上市申报进度。</p><p>该行认为，随着公司全球收入持续增长，经营效率逐步提高，GAAP经营利润有望在未来1-2 个季度内实现扭亏。关注核心管线和早期实体瘤管线进展。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>盘前异动 | 百济神州逆市涨超2%， 替雷利珠单抗在美国正式上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n盘前异动 | 百济神州逆市涨超2%， 替雷利珠单抗在美国正式上市\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-09 17:17 北京时间&nbsp;&nbsp;&nbsp;<strong>老虎资讯综合</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>本周三（10月9日），在中概股普遍大跌的背景下， 百济神州 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。据悉，FDA目前还在对...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1186599914","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186599914","pubTimestamp":1728465437,"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"本周三（10月9日），在中概股普遍大跌的背景下， $百济神州(BGNE)$ 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06160":"百济神州","BGNE":"百济神州"},"translate_title":"Pre-market changes BeiGene bucked the market and rose more than 2%, tislelizumab was officially launched in the United States","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/1110ae0e87a5c84fac15ed2262ef0075","symbols_score_info":{"06160":1.1,"BGNE":1.1},"content_text":"本周三（10月9日），在中概股普遍大跌的背景下， 百济神州 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。中金此前指出，ODAC更新PD-1治疗ESCC+G/GEJ投票进展，该建议仅可能影响百泽安的未来获批Label，但不会影响百泽安的美国上市申报进度。该行认为，随着公司全球收入持续增长，经营效率逐步提高，GAAP经营利润有望在未来1-2 个季度内实现扭亏。关注核心管线和早期实体瘤管线进展。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":358113756082504,"gmtCreate":1728466900102,"gmtModify":1728468656365,"author":{"id":"4191569948696212","authorId":"4191569948696212","name":"freshman1","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4191569948696212","idStr":"4191569948696212"},"htmlText":"cool！","listText":"cool！","text":"cool！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":5,"link":"https://ttm.financial/post/358113756082504","repostId":1186599914,"repostType":2,"repost":{"id":"1186599914","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1728465437,"share":"https://ttm.financial/m/news/1186599914?lang=&edition=fundamental","pubTime":"2024-10-09 17:17","market":"us","language":"zh","title":"盘前异动 | 百济神州逆市涨超2%， 替雷利珠单抗在美国正式上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1186599914","media":"老虎资讯综合","summary":"本周三（10月9日），在中概股普遍大跌的背景下， $百济神州(BGNE)$ 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。","content":"<html><head></head><body><p>本周三（10月9日），在中概股普遍大跌的背景下， <a href=\"https://laohu8.com/S/BGNE\">百济神州</a> 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cd011c248875bdd5b6ca99df21d4878d\" title=\"\" tg-width=\"1224\" tg-height=\"1306\"/></p><p>消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。</p><p>据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。</p><p>中金此前指出，ODAC更新PD-1治疗ESCC+G/GEJ投票进展，该建议仅可能影响百泽安的未来获批Label，但不会影响百泽安的美国上市申报进度。</p><p>该行认为，随着公司全球收入持续增长，经营效率逐步提高，GAAP经营利润有望在未来1-2 个季度内实现扭亏。关注核心管线和早期实体瘤管线进展。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>盘前异动 | 百济神州逆市涨超2%， 替雷利珠单抗在美国正式上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n盘前异动 | 百济神州逆市涨超2%， 替雷利珠单抗在美国正式上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-10-09 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>本周三（10月9日），在中概股普遍大跌的背景下， <a href=\"https://laohu8.com/S/BGNE\">百济神州</a> 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cd011c248875bdd5b6ca99df21d4878d\" title=\"\" tg-width=\"1224\" tg-height=\"1306\"/></p><p>消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。</p><p>据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。</p><p>中金此前指出，ODAC更新PD-1治疗ESCC+G/GEJ投票进展，该建议仅可能影响百泽安的未来获批Label，但不会影响百泽安的美国上市申报进度。</p><p>该行认为，随着公司全球收入持续增长，经营效率逐步提高，GAAP经营利润有望在未来1-2 个季度内实现扭亏。关注核心管线和早期实体瘤管线进展。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"06160":"百济神州","BGNE":"百济神州"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186599914","content_text":"本周三（10月9日），在中概股普遍大跌的背景下， 百济神州 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。中金此前指出，ODAC更新PD-1治疗ESCC+G/GEJ投票进展，该建议仅可能影响百泽安的未来获批Label，但不会影响百泽安的美国上市申报进度。该行认为，随着公司全球收入持续增长，经营效率逐步提高，GAAP经营利润有望在未来1-2 个季度内实现扭亏。关注核心管线和早期实体瘤管线进展。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":358139910242368,"gmtCreate":1728473284469,"gmtModify":1728473289341,"authorId":4191569948696212,"author":{"id":4191569948696212,"idStr":"4191569948696212","authorId":4191569948696212,"name":"freshman1","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":358113756082504,"type":1,"supId":0,"prevId":0,"content":"isdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaefiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaeisdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouasozhsngiejsle<br>","text":"isdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaefiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaeisdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouasozhsngiejsle<br>","html":"isdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaefiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaeisdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouasozhsngiejsle<br>"},{"id":358180857921560,"gmtCreate":1728466919039,"gmtModify":1728468517008,"authorId":4191569948696212,"author":{"id":4191569948696212,"idStr":"4191569948696212","authorId":4191569948696212,"name":"freshman1","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":358113756082504,"type":1,"supId":0,"prevId":0,"content":"fiest repost","text":"fiest repost","html":"fiest repost"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}

盘前异动 | 百济神州逆市涨超2%， 替雷利珠单抗在美国正式上市

Comment（1）

Most Discussed

7x24

盘前异动 | 百济神州逆市涨超2%，替雷利珠单抗在美国正式上市